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Somemonoclonal antibodies (mAbs) recovered from
survivors of filovirus infections can protect against
infection. It is currently unknown whether natural
infection also induces some antibodies with the
capacity for antibody-dependent enhancement
(ADE). A panel of mAbs obtained from human survi-
vors of filovirus infection caused by Ebola, Bundi-
bugyo, or Marburg viruses was evaluated for their
ability to facilitate ADE. ADE was observed readily
with all mAbs examined at sub-neutralizing concen-
trations, and this effect was not restricted to mAbs
with a particular epitope specificity, neutralizing
capacity, or subclass. Blocking of specific Fcg re-
ceptors reduced but did not abolish ADE that was
associatedwith high-affinity binding antibodies, sug-
gesting that lower-affinity interactions still cause
ADE. Mutations of Fc fragments of an mAb that
altered its interaction with Fc receptors rendered
the antibody partially protective in vivo at a low
dose, suggesting that ADE counteracts antibody-
mediated protection and facilitates dissemination
of filovirus infections.
INTRODUCTION
The viral family Filoviridae includes several viruses that
cause severe human diseases with high case fatality rates:
Ebola (EBOV), Bundibugyo (BDBV), Sudan (SUDV), Marburg
(MARV), and Ravn (RAVV) (Burk et al., 2016). Research during
the devastating 2013–2016 outbreak of Ebola virus disease
(EVD) in Western Africa highlighted the lack of understanding
of fundamental characteristics of filovirus pathogenesis and1802 Cell Reports 24, 1802–1815, August 14, 2018 ª 2018 The Autho
This is an open access article under the CC BY-NC-ND license (http://demonstrated an urgent need to develop countermeasures to
combat future outbreaks.
Filoviruses have multiple mechanisms of immune evasion,
including suppression of innate (Messaoudi et al., 2015) and
adaptive (Lubaki et al., 2016) immunity. However, the relative
contributions of these mechanisms to the inability of a host to
control filovirus infections are unclear. Previous reports have
suggested that antibodies may contribute to clearance of filovi-
rus infections. During the 1995 outbreak of EVD in Kikwit, Dem-
ocratic Republic of the Congo, immunoglobulin M (IgM) and IgG
responses appeared in patients on days 8–10 after disease
onset (Ksiazek et al., 1999). Survivors of the 1996 EVD outbreak
in Gabon had greater antibody responses than those that suc-
cumbed (Baize et al., 1999). A detailed characterization of the
immune status of four EVD patients from the 2013–2016
epidemic in Western Africa performed at Emory University
demonstrated that they developed both IgM and IgG responses
during the second week of illness (McElroy et al., 2015). These
data suggest that the appearance of antibodies correlates
with, and may contribute to, clearance of filovirus infections.
This role for antibodies in clearance of acute infections may
pertain to other infections. A recent study that modeled antibody
dynamics during primary dengue virus infections in 53 patients
suggested that antibodies play a key role in clearance of the virus
(Clapham et al., 2016). Some features of murine monoclonal
antibodies (mAbs) specific for filoviruses suggest that the role
of the antibody response in filovirus clearance is complex. For
example, several murine mAbs specific to EBOV (Takada et al.,
2007) or MARV (Nakayama et al., 2011) and human plasma
from EVD survivors (Takada et al., 2003) caused enhancement
of infection in vitro. This phenomenon, known as antibody-
dependent enhancement (ADE), has been demonstrated for
dengue viral infections (Acosta and Bartenschlager, 2016)
and also has been demonstrated for HIV-1 (Tay et al., 2016).
The high lethality and sporadic nature of filovirus infections
prevented investigation of the relevance of ADE for filoviruses;rs.
creativecommons.org/licenses/by-nc-nd/4.0/).
however, some studies with non-human primates suggest this
possibility. Treatment of four EBOV-infected macaques with
convalescent serum from EBOV-immune macaques failed to
protect animals and resulted in viral titers at the time of death
or moribund condition 100-fold greater than those in the con-
trol animals that did not receive immune serum (Jahrling et al.,
2007). Moreover, passive transfer of mAb KZ52 to four rhesus
macaques completely failed to affect the course of infection in
three macaques and significantly delayed death of one ma-
caque. Importantly, in organs harboring the greatest amounts
of virus (liver, spleen, kidney, and lungs), virus loads in the former
three animals were greater than those in the control animal
(Oswald et al., 2007). Eventually, protection by extremely high
doses of polyclonal antibodies (Dye et al., 2012) and mAbs
(Qiu et al., 2012) was achieved. While the complete failure of
the EBOV treatments with antibody doses expected to be
protective and the increased virus loads in organs of recipient
animals suggest the possibility of ADE, it has never been demon-
strated that antibodies isolated from survivors of natural human
EBOV infections can mediate ADE.
Recently, dramatic progress has been achieved in isolation
and characterization of mAbs from human survivors of EVD
caused by infections with EBOV, BDBV, or from a human survi-
vor of MARV disease (MVD), some of which demonstrated
impressive protective efficacy in vivo (Bornholdt et al., 2016;
Corti et al., 2016; Flyak et al., 2015, 2016; Mire et al., 2017). How-
ever, it is unknown whether any of these mAbs also may cause
ADE. Investigation of this possibility could be important for the
rational selection of therapeutic mAbs, doses, and treatment
regimens.
Monocytes, macrophages and dendritic cells (DCs) are potent
antigen-presenting cells that initiate the adaptive immune
response. These cells also are involved in antibody-dependent
phagocytosis of viral particles, as demonstrated for influenza
A virus (Ana-Sosa-Batiz et al., 2016) and HIV-1 (Ana-Sosa-Batiz
et al., 2014). On the other hand, DCs are among the early targets
of infection by filoviruses (Geisbert et al., 2003) and likely
contribute to dissemination of the infection throughout tissues
and organs of the host. Similarly, monocytes, macrophages,
and DCs may be involved in ADE during natural human dengue
infections (Acosta and Bartenschlager, 2016). In the present
study, we investigated the effects of a diverse panel of mAbs
derived from survivors of EVD caused by natural EBOV or
BDBV infections or from a survivor of MVD in multiple types of
immune cells from the monocyte-macrophage lineage. We
found that non-neutralizing antibodies can enhance infection,
and also that neutralizing mAbs, when added at sub-neutralizing
concentrations, exhibit ADE capacity. This enhancing effect was
independent of antibody epitope specificity, neutralizing po-
tency or IgG subclass.
RESULTS
ADEof Filovirus InfectionsCanBeCaused byAntibodies
of Different Epitope Specificities, Different Neutralizing
Capacities, and Different Subclasses
In previous studies, we isolated large and diverse panels of
mAbs from human survivors of EVD caused by BDBV (Flyaket al., 2016), EBOV (P.G., N.K., P.A.I., K.H., A.I.F., A.B., J.E.C.,
B.M. Gunn, A. Bryan, E. Davidson, B.J. Doranz, H.L. Turner,
M.L. Fusco, M.S. Bramble, N.A. Hoff, E. Binshtein, N. Kose,
R. Flinko, C. Orlandi, R. Carnahan, E.H. Parrish, A.M. Sevy,
R.G. Bombardi, P.K. Singh, P. Mukadi, J.J. Muyembe-Tamfum,
M.D. Ohi, E. Ollmann Saphire, G.K. Lewis, G. Alter, A.B. Ward,
and A.W. Rimon, unpublished data) and from a survivor of
MVD (Flyak et al., 2015) specific for the viral glycoprotein (GP),
the only envelope protein of filoviruses (Lee et al., 2008). Most
of these mAbs can be segregated into two groups: (1) those
binding to the receptor-binding domain (RBD) and glycan cap
area located at the N-terminal part of GP1 and (2) those binding
to the membrane proximal external region (MPER) and internal
fusion loop of GP2 (Flyak et al., 2015, 2016, 2018). To test
whether filovirus antibodies from human survivors can cause
ADE, we selected mAbs that recognize diverse epitopes located
either in the RBD/glycan cap or MPER. The choice of mAbs was
based on differences in epitopes, ability to neutralize BDBV and
heterologous ebolaviruses in vitro, levels of protective efficacy
in vivo, and IgG subclasses (Flyak et al., 2016) (Figures S1A
and S1B). To monitor viral infection, we used a chimeric filovirus
carryingGPof BDBV and the rest of the proteins of EBOV (EBOV/
BDBV-GP), and expressing the enhanced GFP (eGFP) from an
added gene (Ilinykh et al., 2016). We treated the monocytic cell
line THP-1 with the selected panel of mAbs at concentrations
100, 10, 1, or 0.1 mg/mL and inoculated them at a multiplicity
of infection (MOI) of 1.0, 0.1, or 0.01 plaque-forming unit (PFU)/
cell (as determined by virus titration in Vero E6 cell monolayers).
The cells were incubated for 48 hr, and the numbers of infected
(eGFP+) cells were quantified by flow cytometry (Figures 1A
and 1B). Strikingly, we detected a reduction in the number of
eGFP+ cells only with the highest concentrations of BDBV270
and BDBV223 mAbs. In all other concentrations, and for each
of the eight mAbs tested, we observed a strong increase in
numbers of infected cells, suggesting enhancement of the infec-
tion. Comparison of the effects of mAb concentrations and
viral doses demonstrated an ADE that was generally greater at
lower (sub-neutralizing) concentrations of mAbs and greater viral
doses, although direct correlations were not observed as each
mAb exhibited its own optimal neutralizing concentration. These
data indicate that enhancement of infection occurs under condi-
tions of incomplete virus neutralization.
Themost pronounced ADEwas detectedwith two of themAbs
specific to the glycan cap region (BDBV52 and BDBV41), the
mAb targeting the internal fusion loop (BDBV259), and the
MPER-specific mAb BDBV317 (Figure 1A). The other glycan
cap-specific mAb BDBV270 and the MPER-specific mAb
BDBV223 demonstrated only very moderate levels of enhance-
ment. BDBV41, BDBV43, and BDBV289 target the same part
of the GP, based on sequence analysis of the GP of escape mu-
tants (Figure S1A) and have comparable 50%maximal inhibitory
concentrations (IC50). However, the enhancement caused by
BDBV41 (1.9- to 21.8-fold increase in the number of infected
cells compared to the no antibody control) was much greater
than that caused by the two other mAbs. The most potent
neutralizing mAb BDBV223 demonstrated the least ADE capac-
ity. These data indicate that ADE of ebolavirus infection does not
depend significantly on the epitope specificity of mAb.Cell Reports 24, 1802–1815, August 14, 2018 1803
Figure 1. ADE of EBOV/BDBV-GP Infection in Primary Monocytes or Monocytic Cell Lines
(A) Heatmaps showing percentages of eGFP+ THP-1 cells at differing concentrations of virus or mAbs, normalized to cells with no mAbs added (100%).
(B) Percentages of eGFP+ THP-1 cells at differing viral doses in the presence of mAbs at 100 mg/mL.
(C) Fold increase over no mAb control of eGFP+ THP-1 and U937 cells infected at MOI of 1.0 PFU/cell and treated with 100 mg/mL of the indicated mAb.
(D) Aggregation of the indicated cells inoculated at an MOI of 1.0 PFU/cell and treated with 100 mg/mL of BDBV52 mAb.
(E) Percentages of eGFP+ THP-1 cells infected at an MOI of 1.0 PFU/cell and treated with the indicated mAb at 100 mg/mL immediately after infection (0 hpi) or at
24 hpi.
(B), (C), (E), mean values ±SD based on triplicate samples. Differences to no antibody control: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Multiple t test).
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Since the percentage of eGFP+ cells was used as ameasure of
ADE, it was important to confirm that mAb-mediated increase of
eGFP+ monocyte numbers results in a higher level of infectious
viral particles released from infected cells (that is, enhanced
infection). However, the presence of neutralizing mAbs in the
medium could interfere with accurate quantification of viable
virions. Therefore, we selected a few representative mAbs with
differing ADE levels demonstrated in Figure 1B (BDBV52,
BDBV41, and BDBV43), inoculated THP-1 cells with virus/mAb
mixtures, incubated for 1 hr, washed cells with PBS, resus-
pended them in fresh medium with no mAbs added, and deter-
mined the virus titers in cell supernatants at 48 hr after infection
(Figure S2). Indeed, the numbers of virions released from the
monocytes infected in presence of filovirus-specific mAbs
were 16.7- to 54.6-fold higher than in the no mAb control, with
no significant difference observed between the irrelevant 2D22
mAb specific for dengue virus (Fibriansah et al., 2015) and the
no mAb groups.
To supplement the data obtained in THP-1 cells, we tested
ADE in an alternative monocytic cell line, U937. Cells were
inoculated with EBOV/BDBV-GP at an MOI of 1.0 PFU/cell
and treated with mAbs BDBV41, BDBV43, or BDBV317.
Again, the mAbs induced ADE, which was even greater than
that observed in THP-1 cells. The greatest increase was
detected for mAb BDBV41 and resulted in a 52-fold
increase in the percentage of eGFP+ cells (Figure 1C). Inter-
estingly, addition of the ADE-inducing mAb BDBV52 to in-
fected THP-1, U937, or primary human monocytic cells
resulted in the formation of large aggregates of infected cells
(Figure 1D).
Next, we tested whether delayed treatment with mAbs also
induced ADE. THP-1 cells were inoculated with EBOV/BDBV-GP
and treated with each of the eight selected BDBV mAbs, either
immediately after addition of the virus or 24 hr later. The delayed
treatment also induced ADE, which was only marginally lower
than that following treatment applied immediately after infection
(Figure 1E).
We next sought to determine whether filovirus mAbs iso-
lated from survivors induced ADE of infections caused by
multiple filoviruses. First, we tested a panel of mAbs recovered
from an EVD survivor of the 2013–2016 epidemic for the ability
to induce ADE of EBOV infection. These mAbs neutralized
EBOV at varying IC50 (Figure S3A). The epitopes of EBOV-
87, EBOV-141, and EBOV-333 are located in the N-terminal
300 amino acids of GP, while that of EBOV-68 and EBOV-91
are in the other part of GP, based on the ability of these
mAbs to bind to secreted GP (sGP) that shares part of its
sequence with the N-terminal part of GP (Sanchez et al.,
1996; Volchkov et al., 1995). We were able to test a new multi-
functional neutralizing mAb EBOV-520 (P.G., N.K., P.A.I., K.H.,
A.I.F., A.B., J.E.C., B.M. Gunn, A. Bryan, E. Davidson, B.J.
Doranz, H.L. Turner, M.L. Fusco, M.S. Bramble, N.A. Hoff, E.
Binshtein, N. Kose, R. Flinko, C. Orlandi, R. Carnahan, E.H.
Parrish, A.M. Sevy, R.G. Bombardi, P.K. Singh, P. Mukadi,
J.J. Muyembe-Tamfum, M.D. Ohi, E. Ollmann Saphire, G.K.
Lewis, G. Alter, A.B. Ward, and A.W. Rimon, unpublished
data), which binds in the region near the internal fusion loop
(IFL) but in an unusual binding pose that alters receptor bind-ing indirectly. We inoculated THP-1 cells with a recombinant
eGFP-expressing EBOV at an MOI of 1.0 PFU/cell and treated
them with mAbs at 100 mg/mL. Only mAbs EBOV-333 and
EBOV-520 slightly reduced the percentage of infected cells,
but not significantly, while all other mAbs demonstrated ADE
ranging from a 2.7- to 15.2-fold increase in infected cells (Fig-
ure S3B). We extended testing of this mAb panel with the well-
characterized EBOV-specific murine-human chimerized mAbs
13C6 and 2G4, which are predecessors of the components
of the ZMapp cocktail (Olinger et al., 2012; Qiu et al., 2011,
2016; Wilson et al., 2000) and bind to glycan cap and GP
base, respectively (Davidson et al., 2015; Murin et al., 2014).
Surprisingly, non-neutralizing 13C6 mAb caused a 50-fold
enhancement of infection when added at 100 mg/mL, whereas
mAb 2G4 demonstrated a strong neutralizing effect (Figures
S3A and S3B).
Further, we tested ADE of SUDV infection. We selected
several mAbs from EVD survivors that neutralized multiple
ebolaviruses including SUDV: BDBV43 used in our previous ex-
periments (Figure 1), BDBV324 (Flyak et al., 2016), EBOV-293
(unpublished data), and EBOV-520 (P.G., N.K., P.A.I., K.H.,
A.I.F., A.B., J.E.C., B.M. Gunn, A. Bryan, E. Davidson, B.J.
Doranz, H.L. Turner, M.L. Fusco, M.S. Bramble, N.A. Hoff, E.
Binshtein, N. Kose, R. Flinko, C. Orlandi, R. Carnahan, E.H.
Parrish, A.M. Sevy, R.G. Bombardi, P.K. Singh, P. Mukadi,
J.J. Muyembe-Tamfum, M.D. Ohi, E. Ollmann Saphire, G.K.
Lewis, G. Alter, A.B. Ward, and A.W. Rimon, unpublished
data). First three mAbs bind to the same antigenic site within
the glycan cap of ebolavirus GP, which is well conserved among
ebolaviruses but EBOV-520 binds to a conformational epitope
in the base region. All mAbs neutralized EBOV, BDBV, and
SUDV in Vero E6 cells at a concentration of 10 mg/mL (Flyak
et al., 2016; unpublished data). Testing these mAbs at the
same concentration in THP-1 cells inoculated with the chimeric
EBOV carrying SUDV GP (EBOV/SUDV-GP) resulted in a
2.3- to 5.6-fold increase in the percentage of infected (eGFP+)
cells, except EBOV-520, which significantly reduced infection
at this concentration (Figure S3C).
To extend the study to MARV, we used a panel of five mAbs
isolated from a MVD survivor: MR72, MR114, MR144, MR191,
or MR228, which belong to different competition-binding groups
on MARV GP and differ in their neutralizing capacity (Flyak et al.,
2015). When THP-1 cells inoculated with a chimeric filovirus
carrying MARV GP (EBOV/MARV-GP) at an MOI of 1.0 PFU/
cell were treated with the mAbs at 100 mg/mL, three out of five
mAbs reduced the infection (Figure S3D). In contrast, treatment
with the same mAbs at a sub-neutralizing concentration of
1 mg/mL resulted in ADE, ranging from a 2.4- to 6.0-fold increase
in the percentage of infected (eGFP+) cells. The only exception
was mAb MR114, which has a very limited binding potency
(Flyak et al., 2015); this antibody neither induced ADE nor
neutralized the virus.
These data suggest that mAbs from human EVD or MVD
survivors possess ADE capacity against both homologous and
heterologous filovirus species recognized by these mAbs.
Furthermore, the effect did not depend significantly on the
epitope specificity of mAbs, the neutralizing capacity, any spe-
cific antibody subclass, or the time of antibody treatment.Cell Reports 24, 1802–1815, August 14, 2018 1805
Figure 2. Aggregation of Virus Particles with mAbs and Co-localization of Aggregates with FcRs
Confocal microscopy of THP-1 cells inoculated with EBOV/BDBV-GP in the presence of BDBV223 mAb (top panel) or in the absence of mAb (bottom panel), 1 hr
after inoculation. FcgRIIIs are stained with antibodies labeled with Alexa Fluor 488 (green), mAbswith Dy594 (orange), or the virus with Alexa Fluor 647 (red). Scale
bar, 5 mm. Nuclei are stained with DAPI (blue). Arrows point to co-localization of FcgRs, mAb, and virus.ADE Depends on the Presence of Fc Fragments and Fcg
Receptors and Is Induced Preferentially by Their High-
Affinity Interactions
It is generally thought that certain pathogens may benefit from
ADE of infection when antibodies bind to virions resulting in
enhanced entry into immune cells bearing Fc receptors (FcRs).
The process is mediated by interactions of FcgRs with the anti-
body Fc region (Swisher and Feldman, 2015). We inoculated
THP-1 cells with EBOV/BDBV-GP with or without the mAb
BDBV223 and incubated for 1 hr; we observed aggregation of
viral particles and co-localization of aggregates with Fc recep-
tors in presence of BDBV223 (Figure 2). To test the involvement
of Fc regions in the observed ADE of filovirus GP-reactive human
mAbs, we evaluated enhancing properties of several mAbs with
their Fc fragments removed. Incubation of infected cells with
F(ab0) or F(ab0)2 fragments of BDBV41 or BDBV43 did not
cause ADE (Figures 3A and S4A). Next, we tested whether the
observed ADE depends on a certain IgG subclass. In the panel
of mAbs selected for testing, BDBV223 was of the IgG3 sub-
class, while the other mAbs were IgG1 molecules. We con-
structed recombinant IgG1, IgG2, IgG3, or IgG4 subclass forms
of mAb BDBV223. This mAb neutralized EBOV/BDBV-GP effec-
tively when engineered to contain the Fc of any of the sub-
classes, with IgG2 and IgG3 being the most potent against
EBOV (Table S1). We tested the Fc-modified mAbs for the ability
to induce ADE at concentrations of 0.1 or 1 mg/mL in THP-1 cells
inoculated with EBOV/BDBV-GP or EBOV at an MOI of 1.0 PFU/
cell. Antibody of the IgG3 subclass induced high-level ADE at
both concentrations tested with both viruses, while antibody of1806 Cell Reports 24, 1802–1815, August 14, 2018the other subclasses induced much lower (IgG1, IgG4) or
no (IgG2) ADE (Figures S4A and S4B). When cells were inocu-
lated with EBOV, which is less sensitive to neutralization by
BDBV223 (Figure S4B), ADE was observed with the IgG1 sub-
class. Both the hybridoma-derived native BDBV223 IgG3 and
its recombinant IgG3 form induced a much greater level of
ADE with EBOV (50-fold) than with EBOV/BDBV-GP (2- to
8-fold) (Figures S4A and S4B), which is likely related to a lesser
affinity of this mAb for binding to the EBOV GP. The ADE effect
was greater for the recombinant IgG3 than for the hybridoma-
produced antibody, presumably due to a difference in glycosyl-
ation of asparagine 297 in the Fc domain of the heavy chain
(Borrok et al., 2012), which is known for its heterogeneity (Higel
et al., 2016), or another glycosylated amino acid residue.
We examined the effects of blocking each of the three types
of Fcg receptors, FcgRI, FcgRII, or FcgRIII, on ADE. THP-1 cells
were inoculated with FcR-blocking antibodies for 1 hr, treated
with recombinant BDBV223 IgG1, IgG2, IgG3, or IgG4 mAbs
at a concentration 0.1 mg/mL, and inoculated with EBOV/
BDBV-GP at an MOI of 1.0 PFU/cell (Figure 3B). As recombinant
IgG1, IgG2, or IgG4 did not cause ADE, blocking of any of the
receptors resulted in little or no effect. In contract, when IgG3
was used, blocking of FcgRIII eliminated ADE, while blocking
of FcgRI or FcgRII significantly reduced it. Testing of hybrid-
oma-produced BDBV223 antibody with EBOV, which is less
sensitive to this mAb (Figure S1B), also demonstrated the great-
est reduction of ADE by blocking of FcgRIII and much lesser
effects by blocking of FcgRI or FcgRII (Figure 3C). These data
are surprising, because a single THP-1 cell expresses FcgRI
Figure 3. ADE Depends on the Presence of Fc Receptors, Fc Fragments, and on the Subclass of IgG: Fold Increases of the Percentages of
Infected (eGFP+) THP-1 Cells Treatedwith the Indicated FilovirusmAbwith or without FcgR-Blocking Antibodies, over Cells Not Treatedwith
Filovirus mAbs
In all experiments, MOI of 1 PFU/cell was used.
(A) Cells inoculated with EBOV/BDBV-GP and treated with 10 mg/mL of various forms of BDBV41 or BDBV43: H, hybridoma derived BDBV41; N, plant-derived
BDBV43; KA and LALA, modifications of Fc fragments; F(ab0)2 fragments generated by pepsin digestion; F(ab0) fragments generated by papain digestion.
(B) Cells infected with EBOV/BDBV-GP and treated with 0.1 mg/mL of hybridoma-produced BDBV223 or recombinant forms of BDBV223 with differing sub-
classes, in the presence of FcgR-blocking antibodies.
(C) Cells inoculated with the indicated viruses and treated with 0.1 mg/mL BDBV223 in presence of the indicated FcgR-blocking antibodies.
(D) Cells inoculated with EBOV/BDBV-GP and treated with the indicated mAbs (10 mg/mL) in the presence of the indicated FcgR-blocking antibodies.
(E) Cells infected with EBOV-eGFP at MOI of 1.0 PFU/cell and treated with the indicated concentrations of EBOV-520 or EBOV-520-LALA.
Mean values ± SD based on triplicate samples. Differences to no antibody control (A) or for the indicated pairs: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
(multiple t test).with 35,000 high-affinity binding sites for IgG1 and 50,000
low-affinity FcgRII for IgG2 on the cell surface (Fleit and Koba-
siuk, 1991), but expression of FcgRIII in these cells is limited
and was demonstrated only recently (Tay et al., 2016). Interest-ingly, unlike these data, dengue ADE is associated primarily
with FcgRI and FcgRII (Acosta and Bartenschlager, 2016; Littaua
et al., 1990). The remaining BDBV mAbs used in these experi-
ments were of the IgG1 subclass. In contrast to BDBV223,Cell Reports 24, 1802–1815, August 14, 2018 1807
a significant inhibition of ADE for these mAbs was observed with
blocking of FcgRI, but not FcgRII or FcgRIII (Figure 3D), which is
consistent with the highest binding affinity of FcgRI for IgG1
(Gillis et al., 2014).
We also evaluated the effect of antibody Fc region mutations
L234A and L235A (LALA) (Reusch and Tejada, 2015), which
reduce antibody binding to FcgRIIa and FcgRIIIa but not FcgRI
(Hessell et al., 2007), on the induction of ADE. Introduction of
the mutations in mAbs BDBV41 and BDBV43, which are IgG1,
only slightly reduced ADE (Figure 3A). These data are consistent
with the preferential binding of IgG1 to FcgRI. The LALAmutation
of EBOV-520 (IgG1 subclass aswell) abrogated ADE in vitro even
more efficiently (Figures 3E and S4C, see below). Next, we
tested the effect of the Fc region mutation K322A (KA), the res-
idue that is critical for antibody-dependent complement activa-
tion (Thommesen et al., 2000). We did not observe an effect for
this mutation (Figure 3A), suggesting that complement does
not play a role in the observed ADE.
Taken together, these data indicate that ADE of filovirus infec-
tions involves interaction of Fc receptors with Fc domains of an-
tibodies. The data also demonstrate that blocking of an FcgR
preferentially interacting with an antibody subclass that causes
ADE significantly reduces but does not completely eliminate
the ADE. This suggests that low-affinity interactions between an-
tibodies and FcgRs also may contribute ADE, albeit at a lesser
extent.
Induction of ADE in Primary Human Immune Cells
As cell lines of tumor origin may exhibit different physiologic and
expression patterns compared to primary cells, we evaluated
ADE in total peripheral blood mononuclear cells (PBMCs) and
various myeloid cell types, including monocytes, immature
DCs, mature DCs, and macrophages obtained from human do-
nors and differentiated in vitro (Figure 4). These cells differ in their
expression patterns of Fc receptors, which change during their
differentiation and maturation. Each of these cell types sup-
ported EBOV/BDBV-GP infection but at very different levels
andwith a high donor-to-donor variability. MAbs caused variable
ADE of an infection in each of the cell types obtained from many
but not all donors. The PBMC samples revealed low susceptibil-
ity to infection, ranging from 0.2% to 6% of infected (eGFP+)
cells, which reflects the relatively low percentages of putative fi-
lovirus-susceptible target cells present (e.g., monocytes) and
perhaps viral uptake by non-susceptible cells expressing Fc re-
ceptors. Analysis of ADE in these cells demonstrated an increase
(up to 3.8-fold) in the percentages of infected cells, compared to
the no antibody control, for some donor-mAb combinations. In
contrast, primary monocytes weremore susceptible to infection,
with the proportion of eGFP+ cells ranging from 7% to 37% be-
tween donors. The ADE observed in these cells was comparable
in magnitude to that in PBMCs (Figure 4). However, taking into
consideration the higher absolute levels of infection in primary
monocytes, this magnitude of enhancement may drastically
increase the amount of virus circulating in blood of infected
patients. Immature or mature DCs demonstrated similar
susceptibility to EBOV infection (3%–22% or 3%–21% infected
cells, respectively, as in our previous study, (Lubaki et al.,
2013), which is somewhat lower than that observed for mono-1808 Cell Reports 24, 1802–1815, August 14, 2018cytes. Both types of DCs showed induction of ADE at a lower
level compared to that in PBMCs or monocytes. Macrophages
demonstrated a high susceptibility to infection with 10%–32%
of infected cells, which is comparable to monocytes, and ADE
was observed at levels comparable to those in immature or
mature DCs. To test whether the virus produced in primary im-
mune cells may transfer infection to other cells efficiently, we
inoculated PBMCs with EBOV/BDBV-GP at an MOI of 1.0
PFU/cell for 24 hr, washed them twice with phosphate-buffered
saline (PBS), and placed the infected cells on top of uninfected
Vero E6 cell monolayers. The plates were incubated for 48 hr,
then PBMCs were removed, Vero E6 monolayers were washed
with PBS and trypsinized, and the proportion of eGFP+ Vero
E6 cells was measured by flow cytometry. Vero E6 cells incu-
bated with infected PBMCs from three donors showed the per-
centages of infected (eGFP+) cells ranging from 45% to 67%
(Figure S5). This additional line of evidence shows that ADE
caused bymAbs in immune cells may enhance the virus dissem-
ination to the other cells.
These data demonstrate that human mAbs facilitate ADE in
primary human immune cells at levels that vary greatly depend-
ing on the cell type, with the highest level in monocytes.
Moreover, infected PBMCs efficiently transmitted infection to
non-immune cells, suggesting that ADE may contribute to
enhancement of virus spread through tissues and organs.
An Antibody with Mutated Fc Domain, but Not the
Original Antibody, Protects Laboratory Mice from EBOV
Infection
There is nomousemodel for BDBV, andmany of the BDBVmAbs
in the panel do not neutralize EBOV. Therefore, to address the
physiological relevance of the observed ability of mAbs to
enhance EBOV infection in vivo, we studied in more detail the
mAb EBOV-520, which was isolated from a human survivor of
the 2013–2016 EBOV epidemic in Western Africa in our recent
study (P.G., N.K., P.A.I., K.H., A.I.F., A.B., J.E.C., B.M. Gunn,
A. Bryan, E. Davidson, B.J. Doranz, H.L. Turner, M.L. Fusco,
M.S. Bramble, N.A. Hoff, E. Binshtein, N. Kose, R. Flinko,
C. Orlandi, R. Carnahan, E.H. Parrish, A.M. Sevy, R.G. Bom-
bardi, P.K. Singh, P. Mukadi, J.J. Muyembe-Tamfum, M.D.
Ohi, E. Ollmann Saphire, G.K. Lewis, G. Alter, A.B. Ward, and
A.W. Rimon, unpublished data). One hundred micrograms of
the mAb uniformly protects laboratory mice against lethal
EBOV infection when administered 24 hr after challenge (P.G.,
N.K., P.A.I., K.H., A.I.F., A.B., J.E.C., B.M. Gunn, A. Bryan, E. Da-
vidson, B.J. Doranz, H.L. Turner, M.L. Fusco,M.S. Bramble, N.A.
Hoff, E. Binshtein, N. Kose, R. Flinko, C. Orlandi, R. Carnahan,
E.H. Parrish, A.M. Sevy, R.G. Bombardi, P.K. Singh, P. Mukadi,
J.J. Muyembe-Tamfum, M.D. Ohi, E. Ollmann Saphire, G.K.
Lewis, G. Alter, A.B. Ward, and A.W. Rimon, unpublished
data). As the original mAb is of the IgG4 subclass, we generated
a recombinant IgG1 form of the mAb in order to increase the
affinity of binding to FcgRs (Bournazos and Ravetch, 2017).
Two recombinant forms of the IgG1 subclass of the mAb were
produced: the non-mutated (wild-type) and a variant IgG1 deriv-
ative with L234A/L235A (LALA) mutations in the Fc fragment to
reduce FcR binding. As noted above, EBOV-520 IgG1, but not
EBOV-520 IgG1/LALA, caused ADE in EBOV-infected THP-1
Figure 4. ADE of EBOV Infection in Primary Human Immune Cells
Left, fold increase in percentage of infected (eGFP+) cells due to the presence of the filovirus mAb indicated on the x axis. Right, percentage of infected (eGFP+)
cells in the presence or absence of filovirus mAbs indicated on the x axis, mean values ± SD based on triplicate samples. Cells from individual donors are
indicated with various symbols. Differences to no antibody control (multiple t test): *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. ADE Counteracts Antibody-Mediated Protection In Vivo
EBOV-520 IgG1/LALA, but not EBOV-520 IgG1, protects laboratory mice from EBOV infection at a low dose. Kaplan-Meier survival curves, body weight, and
illness score curves are shown. *Survival difference between the EBOV-520 IgG1 and EBOV-520 IgG1/LALA recipients: p = 0.0298 (Mantel-Cox test).cells at low doses (Figures 3E and S4C). Groups of BALB/c lab-
oratory mice were inoculated with 1,000 PFU of mouse-adapted
EBOV, strain Mayinga (Bray et al., 1998), and 24 hr later treated
by the intraperitoneal route with a low dose (20 mg per mouse) of
wild-type EBOV-520 IgG1 or EBOV-520 IgG1/LALA. EBOV-520
IgG1 did not mediate protection at this low dose, while 60% of
mice treated with EBOV-520 IgG1/LALA survived (Figure 5).
Since the disruption of Fc-FcgR interactions by introduction of
the LALA mutations is expected to reduce the ability of EBOV-
520 to enhance infection, the protective effect observed after
low-dose EBOV-520 IgG1/LALA is associated with disabling
the enhancement potential in vivo that occurs when the mAb is
present only in low concentration.
DISCUSSION
ADE caused by EBOV GP-specific mAbs was first described by
Takada et al. in 2001 using murine mAbs (Takada et al., 2001). It
was hypothesized that ADE depends on epitope specificity of1810 Cell Reports 24, 1802–1815, August 14, 2018mAbs (Nakayama et al., 2011; Takada et al., 2001, 2007). How-
ever, we found that ADE with human mAbs does not depend on
the specific region of GP targeted by mAbs, similarly to ADE
observed during dengue infection (Morens et al., 1987). Indeed,
we observed ADE of EBOV and EBOV/BDBV-GP infections
mediated by mAbs that recognize the glycan cap, the internal
fusion loop, or the MPER (Figures 1B, S1, and S3A–S3D).
Some mAbs targeting the EBOV GP glycan cap were found to
cause ADE even at a high concentration of 100 mg/mL and an
MOI of 1.0 PFU/cell (BDBV41, BDBV52, BDBV43, EBOV87,
13C6), whereas others (BDBV270, BDBV289) with a similar
epitope specificity did not. Induction of ADE may depend on
fine differences in epitope specificity or differing binding
poses of mAbs on similar epitopes. The MPER-specific mAb
BDBV317 caused ADE at a much greater concentration than
another MPER-specific mAb BDBV223 (Figure 1A). Moreover,
EBOV-68 and EBOV-91, which bind to the C-terminal region of
GP but do not neutralize EBOV (Figure S3A), increased the infec-
tion by 4- to 6-fold at 100 mg/mL (Figure S3B). These data
suggest that each mAb has its own optimal concentration for
neutralization, whereas at a lesser non-neutralizing concentra-
tion, it can cause ADE. Non-neutralizing mAbs appear to have
the capacity to cause ADE even at high concentrations.
Antibodies recognize virus and engage Fc receptors on
phagocytes, causing them to internalize virus-antibody com-
plexes by FcgR-mediated phagocytosis. If virus is not neutral-
ized, this enhanced entry mechanism may mediate ADE (Chan
et al., 2015; Flipse et al., 2013). However, ADE is not always
observed in these settings, perhaps due to the destruction of
pathogens in lysosomes or for other reasons (Halstead, 1994).
In experiments with flaviviruses, formation of large antibody-
virus aggregates with multiple viral particles was observed;
moreover, the aggregates appeared to be taken up by macro-
phages (Gollins and Porterfield, 1985). Our experiments also
demonstrated aggregation of viral particles in monocytic cells
(Figure 2), which also could result in their increased uptake.
Engagement of Fcg receptors leads to reorganization of cyto-
skeleton and membrane remodeling resulting in enhancement
of viral entry (Tay et al., 2016). Accordingly, disruption of the
cytoplasmic tail of FcgRI and FcgRIIa reportedly abolished
ADE (Furuyama et al., 2016; Rodrigo et al., 2006). FcgRIII recep-
tors were demonstrated to promote ADE via transmission of a
phagocytic signal after activation (Park et al., 1993). As
expected, we did not observe ADE in this study in the absence
of Fc-mediated viral uptake (Figures 3A and S4A), suggesting
that elimination of ADE by modification of Fc regions may be
an attractive way to improve potency of mAbs (Williams et al.,
2013).
Immunoglobulin subclass Fc domains have varying affinities
to Fcg receptors (Hogarth and Pietersz, 2012), and consequently
they mediate varying levels of effector function and phagocytic
activity. The affinity of human immunoglobulins for binding to
Fcg receptors in immune complexes formed by antibody and
viral antigens may differ from that of free immunoglobulins.
Immune complexes formed with human IgG1, IgG3, and IgG4
bind preferentially to FcgRI, FcgRIIa, and FcgRIIIa, while those
formed by IgG2 bind preferentially to FcgRIIa and FcgRIIIa
(Bruhns et al., 2009; Liu, 2015; Tay et al., 2016). In our study,
blocking of different FcgRs had differing blocking effects on
the occurrence of ADE, which also differed for IgG1 and IgG3
mAbs: FcgRI > FcgRII > FcgRIII, and FcgRIII > FcgRI > FcgRII,
respectively (Figures 3C and 3D). These data are consistent
with different binding affinities of antibody subclasses to each
type of Fcg receptor. Blocking of FcgRI binding effectively abro-
gated ADE caused by the highly interacting subclass IgG1 (mAbs
BDBV41, BDBV43, BDBV52) (Figure 3D) and less by subclass
IgG3 antibodies (mAb BDBV223) (Figure 3C). However, blocking
of FcgRIII led to elimination of ADE mediated by IgG3 but
not IgG1 antibodies (Figure 3D). A possible explanation for these
data is the low expression of FcgRIII receptors in THP-1 cells and
high expression of FcgRI (Tay et al., 2016). Similarly, change of
IgG1 to IgG2 or IgG4 subclasses reduced ADE of dengue virus
infection in THP-1 cells (Ramadhany et al., 2015), which bear
FcgRI and FcgRII; the affinity of interactions of FcgRII with
IgGs is much lower (Swisher and Feldman, 2015). Interestingly,
in K562 monocytic cells bearing only FcgRII, the greatest level
of ADE in experiments with dengue virus was induced by theIgG2 subclass of D23-11G7C2 mAb (Ramadhany et al., 2015).
Consistent with that finding, ADE of EBOV infection in K562 cells
also was documented for IgG2 murine mAbs (Takada et al.,
2007). These data suggest that induction of ADE depends greatly
on the affinity between an antibody subclass and the specific
FcgR.
The LALA mutation of IgG1 mAbs BDBV41 and BDBV43 only
slightly decreased ADE (Figure 3A). The LALA mutation initially
was suggested to completely abolish binding to FcgRI (Hezareh
et al., 2001) but later was shown to reduce binding to FcgRIIa
and FcgRIIIa but not FcgRI (Hessell et al., 2007); the effects
were related to change in Fc glycosylation (Reusch and Tejada,
2015). These data are consistent with preferential binding of
IgG1 to FcgRI and the results of blocking FcgRs on induction
of ADE by IgG1 (Figure 3B). Similarly, the KA mutation did
not affect the level of ADE (Figure 3A). This mutation disables
antibody-mediated complement activation (Thommesen et al.,
2000) but only slightly reduces the binding affinity to FcgRIIa or
FcgRIIIa and does not affect binding to FcgRI (Hezareh et al.,
2001).
Our initial experiments were performed with two monocytic
cell lines, which both demonstrated a low susceptibility to
EBOV, consistent with previously published data (Martinez
et al., 2013). In contrast, primary monocytes are highly permis-
sive for EBOV infection (Stro¨her et al., 2001). The low susceptibil-
ity of monocytic cell lines to infection may be explained by their
deficiency in b1 integrins, which serve as an attachment factor of
monocytes for EBOV (Dube et al., 2008). In addition, differentia-
tion of THP-1 cells and expression of interferon-inducible trans-
membrane proteins promotes EBOV entry (Martinez et al., 2013).
We observed a significant difference in virus susceptibility of the
two human monocytic cell lines tested: 48 hr after infection with
EBOV/BDBV-GP at 1.0 PFU/cell, the percentages of infected
U937 cells varied from 0.5% to 1.3% (Figure 1C), but THP-1 cells
varied from 3% to 8% (Figure 1C). Importantly, cells with lower
susceptibility demonstrated higher levels of ADE: addition of
BDBV41 resulted in a 50-fold increase of infected U937 cells
but only a 6-fold increase of infected THP-1 cells (Figure 1C).
In humans, FcgRs have been detected on T and B lympho-
cytes, natural killer (NK) cells, neutrophils, granulocytes, mono-
cytes, macrophages, and DCs (Nimmerjahn and Ravetch,
2008). To validate the cell line results above in primary human
immune cells, we used total PBMCs, monocytes, immature,
and mature DCs or macrophages obtained from human donors.
Remarkable similarities have been identified between EBOV and
dengue ADE in primary human myeloid cells (Halstead and
O’Rourke, 1977; Halstead et al., 1977). Testing of filovirus infec-
tion in PBMCs demonstrated their very low susceptibility to
infection, while that of primary monocytes, immature andmature
DCs, and macrophages was markedly higher (Figure 4). Of inter-
est, it has also been concluded that in vitro, dengue virus repli-
cates in immature monocytes (Halstead et al., 1977). Moreover,
dengue virus has been recovered from monocytes circulating in
patients with acute dengue infection (Durbin et al., 2008), but this
phenomenon is probably an adjunct to the predominant replica-
tion of virus in tissue macrophages (Aye et al., 2014). We found
that EBOV-infected PBMCs transferred the virus to Vero E6 cells
(Figure S5), suggesting that ADEmay promote spread of filovirusCell Reports 24, 1802–1815, August 14, 2018 1811
infection through various tissues. In the case of dengue ADE, an
8.5-fold increase of the proportion of infected primary human
monocytes was accompanied with a 60-fold increase in the total
virus output (Kou et al., 2011).
As was observed earlier during dengue infection (Boonnak
et al., 2011), we found a very high donor-to-donor variability in
susceptibility of primary immune cells to infection and ADE,
which may be explained by differing levels of various cell surface
molecules among samples. For example, primary human mono-
cytes exhibit an extreme variability in expression of the inhibitory
FcgRIIb, ranging from 1% to 48% (Boruchov et al., 2005). It is
known that FcgRIIb limits phagocytosis (Liu et al., 2006), which
is important for ADE. The low susceptibility of PBMC to EBOV
infection may be explained by their low level of differentiation.
The high donor-to-donor variability in susceptibility of primary
monocytes to EBOV in our experiments (Figure 4) likely is
explained by the extreme variability of expression of the inhibi-
tory FcgRIIb in primary human monocytes (Boruchov et al.,
2005) and the limitation of phagocytosis by FcgRIIb (Liu et al.,
2006). Similarly, the extreme donor-to-donor variability in the
levels of FcgRs and filovirus attachment factors may play a
role in the varying levels of infection and ADE observed in the
other primary immune cells tested.
As these data demonstrate that ADE can be caused by anti-
bodies of different specificity and different subclasses, the ability
of filovirus antibodies to cause ADE may be a consequence of
some idiosyncratic features of filovirus particles, rather than an-
tibodies themselves. For example, the unusual length of filovirus
particles, typically around 1 mM (Bharat et al., 2012), requires a
large number of antibodies to saturate all GP spikes. It is possible
that an incomplete saturation of antibodies on surface GP mole-
cules results in ADE rather than neutralization. Finally, we
demonstrated that ADE caused by a human EBOV-520 mAb
in vitro is abrogated by mutagenesis of Fc domain (Figures 3E
and S4C), and Fc-mediated effects prevent effective protection
mediated by the same mAb in vivo (Figure 5).
These data have important implications for treatment of filovi-
rus infections with passively transferred antibodies and for vac-
cinations. Low, sub-neutralizing concentrations of antibodies
may cause ADE, suggesting that only very high concentrations
of mAbs should be used for treatment of filovirus infections. Mul-
tiple failures of the early attempts to treat filovirus infections by
passively transferred antibodies might be explained by insuffi-
ciently high doses of antibodies administered (reviewed in
Kuhn, 2008). In contrast, the more recent successful experi-
mental antibody treatments of filovirus infections used extremely
high concentrations of monoclonal (Corti et al., 2016; Qiu et al.,
2012, 2014) or polyclonal (Dye et al., 2012; Kudoyarova-
Zubavichene et al., 1999; Pyankov et al., 2017) antibodies, which
are likely to overcome the ADE effect. In this context, introduc-
tion of mutations in Fc domains that disable the interaction
with Fcg receptors may be desirable. However, the Fc-FcgR
interaction also may contribute to antibody-mediated protection
through Fc-mediated activation of phagocytic immune cells that
contribute virus clearance and through activation of comple-
ment. Therefore, the complexity of interaction of therapeutic
antibodies with immune cells should be considered carefully.
Similarly, the success over the past decade in development of1812 Cell Reports 24, 1802–1815, August 14, 2018filovirus vaccines is mostly associated with vaccine vectors
able to replicate at very high levels, such as vesicular stomatitis
virus, and/or administration of very high vaccine doses (Henao-
Restrepo et al., 2015; Martins et al., 2016). As antibody levels
in vaccinees wane over time, low concentrations of antibodies
might contribute to ADE during subsequent filovirus exposure.
This possibility should be carefully explored in experimentally
vaccinated animals.
This study resulted in several important conclusions. First, filo-
virus GP-specific antibodies from human survivors present at
low concentrations are capable of inducing ADE in vitro, sug-
gesting that low levels of antibodies early after filovirus infections
in humans may facilitate virus spread. Second, ADE can be
caused by antibodies of various epitope specificities, neutral-
izing capacities and subclasses. Third, the ability of primary
human immune cells to participate in ADE of infection varies
greatly between cell types and is most pronounced in mono-
cytes. Fourth, mutating the Fc domain to disable Fc-FcgR inter-
actions can enhance protection of a neutralizing antibody at low
concentrations in vivo; hence, modification of the Fc region may
increase the therapeutic efficacy of antibody treatments for
EBOV-infected patients. Importantly, the data suggest that the
dose of therapeutic mAbs injected to filovirus patients must be
sufficiently high to achieve virus neutralizing concentrations
in vivo, as lower doses may cause an opposite effect and
enhance the infection.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Viruses and cell lines
The following filoviruses were used in the study: the recombinant EBOV expressing eGFP from an added transcriptional cassette
(Towner et al., 2005), and its derivatives in which GP was replaced with its counterpart from BDBV (EBOV/BDBV-GP), SUDV
(EBOV/SUDV-GP) and MARV (EBOV/MARV-GP) (Ilinykh et al., 2016), and mouse-adapted EBOV strain Mayinga (Bray et al.,
1998). The viruses were propagated in Vero E6 cells and titrated in monolayers of Vero E6 cells (ATCC). Following a 1 hr-long adsorp-
tion, virus dilutions were covered with 0.4% methylcellulose overlay in MEM medium (ThermoFisher Scientific) containing 2% fetal
bovine serum (HyClone). Plates were incubated at 37C with 5% CO2 for three days, and plaques were counted using a fluorescent
microscope. The pro-monocytic human myeloid leukemia cell line U937 (ATCC) and the human monocytic leukemia cell line THP-1
(ATCC) were cultured in RPMI 1640medium (ThermoFisher Scientific) supplemented with 10% fetal bovine serum (HyClone) at 37C
with 5% CO2. All work with filoviruses was performed in the BSL-4 facility of the Galveston National Laboratory.
Isolation and culture of primary human immune cells
Blood samples were collected from anonymous healthy adult donors at the UTMB Blood Bank according to a clinical protocol
approved by the UTMB Institutional Review Board. Buffy coats from blood samples were used for isolation of PBMCs by density
gradient centrifugation in Ficoll (Histopaque; Sigma-Aldrich). CD14+ monocytes were purified using anti-human CD14 antibody-
labeled magnetic beads and magnetic LS columns (Miltenyi Biotec) and used immediately or further differentiated into DCs or
macrophages. Isolated monocytes typically showed > 90% positivity for CD14 staining by flow cytometry. Monocytes were plated
at 0.73 106 to 13 106 cells/mL in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (HyClone) and either 500 U/mL
of human granulocyte-macrophage colony-stimulating factor (GM-CSF; Peprotech) and 500 U/mL of human interleukin-4 (IL-4;
Peprotech) to differentiate into immature DCs, or 20-50 ng/mL of macrophage colony-stimulating factor (M-CSF; Peprotech) to
differentiate into macrophages and cultured for 7 days. Immature DCs expressed surface CD11c, CD1c, and HLA-DR and were
low in CD14, whereas macrophages retained high levels of CD14 and were HLA-DR positive as determined by flow cytometry.
To generate mature DCs, MoDC maturation (Miltenyi Biotec) medium was added to immature DCs, and cells were incubated for
an additional 3 days.
In vivo experiments
The animal protocol for testing of mAbs in laboratory mice was approved by the UTMB Institutional Animal Care and Use Committee.
Seven-week-old BALB/c laboratory mice (Charles River Laboratories) were placed in the ABSL-4 facility of the Galveston National
Laboratory. Groups of laboratory mice at 4-5 animals per group were injected intraperitoneally with 1,000 PFU of themouse-adapted
EBOV. Twenty-four hours later, animals were injected with 20 mg mAbs by the intraperitoneal route. Animals treated with 2D22 mAb
served as controls. The animal observation procedure was performed as previously described (Flyak et al., 2016). The overall
observation period lasted for 28 days.
METHOD DETAILS
Preparation of human mAbs, their mutated versions and Fab fragments
Human hybridoma cell lines were expanded in post-fusion medium, as previously described (Flyak et al., 2015). Supernatants
from cultured hybridoma cells were collected, clarified by low-speed centrifugation and filtered. HiTrap Protein G or HiTrap
MabSelectSure columns were used to purify antibodies from filtered supernatants. F(ab0) fragments were generated by papain
digestion, as described previously (Flyak et al., 2015) and F(ab0)2 fragments were produced by pepsin digestion. Generation and
characterization of BDBV-specific mAbs was described previously (Flyak et al., 2016). Plant-derived BDBV43 was generated as
previously described (Zeitlin et al., 2011). Genes encoding the immunoglobulins with variant Fc region were synthesized on a BioXP
DNA synthesizer (Synthetic Genomics) and Gibson cloned into an antibody expression vector. Plasmid maxiprep DNAs were pre-
pared in E. coli and purified using commercial DNA kits (QIAGEN). DNAs were used to transfect 293F cells (ThermoFisher Scientific)
for recombinant antibody expression. IgGs were purified from transfected cell supernatants by chromatography using HiTrap
Protein G or HiTrap MabSelectSure columns.
mAb-mediated enhancement of immune cells infection by filoviruses
The monocytic cell lines (THP-1, U937) or primary human immune cells (PBMCs, monocytes, DCs or macrophages) were pre-
incubated in 24-well plates at 2 3 105 cells per well with mAbs at indicated concentrations for 1 hour, inoculated with EBOV,
EBOV/BDBV-GP, EBOV/SUDV-GP or EBOV/MARV-GP viruses at an indicatedMOI, and incubated at 37Cwith 5%CO2. At 48 hours
(or 0 or 24 hours where indicated) after inoculation, cells were harvested by low-speed centrifugation (200 x g, 10 min), washed once
with PBS, fixed with 4% paraformaldehyde and analyzed by flow cytometry. In a separate experiment, THP-1 cells were pre-
incubated with mAbs at 100 mg/mL for 1 hour, inoculated with EBOV/BDBV-GP at an MOI of 1 PFU/cell and incubated for 1 hour
at 37C, 5% CO2. Then, cells were washed 3 times with PBS, resuspended in RPMI 1640 medium with 10% fetal bovine serume3 Cell Reports 24, 1802–1815.e1–e5, August 14, 2018
and incubated at 37C with 5% CO2. At 48 hours after infection, cell suspensions were centrifuged at 200 x g for 5 min, and super-
natants were harvested and titrated on Vero E6 monolayers as described above.
Spread of infection from PBMCs to Vero E6 cells
Isolated PBMCs in 24-well plates at 2 3 105 cells per well were inoculated with EBOV/BDBV-GP virus at an MOI of 1 PFU/cell, and
incubated at 37C with 5% CO2. At 24 hours after infection, cells were harvested by low-speed centrifugation (200 x g, 5 min),
resuspended in 1 mL MEM medium with 10% fetal bovine serum and placed at the top of Vero E6 cell monolayers, and incubated
for 48 hours at 37C with 5% CO2. Next, monolayers were washed 3 times with PBS to remove PBMCs and residues of MEM
medium. Vero E6 cells then were treated with trypsin, harvested, washed twice with PBS and fixed with 4% paraformaldehyde
for the subsequent flow cytometry analysis.
Flow cytometry
Following infection with recombinant filoviruses expressing eGFP, cells were fixed in 4%paraformaldehyde for 24 hours, followed by
a second fixation in fresh paraformaldehyde, and then taken out of the BSL-4 facility according the approved standard operation
procedure. Then, fixed cells were centrifuged at 450 x g for 10 min, resuspended in PBS and analyzed by analytical flow cytometry
using an Accuri C6 or LSRII Fortessa cytometer (both BD Biosciences) at the UTMB Flow Cytometry Core Facility. The acquired data
were analyzed using FlowJo 7.6.1 software (Tree Star). The percentages of eGFP+ cells in total cell populations were calculated.
Selection of EBOV/BDBV-GP escape mutants
To select escapemutants, 100PFUof EBOV/BDBV-GPwere combinedwith 2-fold dilutions ofmAbs starting at 200mg/mL in u-bottom
96-well plates and incubated for 1 hour at 37C. Mixtures were placed on Vero E6 cell monolayers in flat bottom 96-well plates and
incubated for 1 hour. Supernatants were removed, fresh mAbs were added at the same concentrations in 200 mL of MEM supple-
mented with 2% FBS, and cells were incubated for 7 days at 37C. Supernatants from wells in which viral replication was observed
in the presence of the highest concentrations of mAbs, as determined by UV microscopy, were collected. 20 mL aliquots were incu-
bated with 2-fold dilutions of mAbs starting at 200 mg/mL, and viruses were propagated in the presence of mAbs as above. The pro-
cedure was repeated once more with mAb dilutions starting at 400 mg/mL. Viruses that replicated at the highest mAb concentrations
were amplified in Vero E6 cell culturemonolayers in 24-well plates in the presence ofmAbs at 200 mg/mL for 7 days. RNAwas isolated
from infected cells using TRIzol, and GP genes were RT-PCR-amplified and sequenced. To determine susceptibility of the isolated
escapemutants tomAbs, 100 PFU of the viruses inMEMsupplementedwith 2%FBS in triplicate were combined in U-bottom 96-well
plates with 8 to 12 two-fold dilutions of mAbs, staring at 200 mg/mL, in total volumes of 50 mL, and incubated for 1 hr at 37C. The
virus/antibody mixtures then were placed in triplicate Vero E6 cell culture monolayers in 96-well plates, incubated for 1 hr at 37C,
washed with MEM, overlaid with 200 mL of MEM containing 2% FBS and 0.8%methylcellulose, and incubated for 48 hours at 37C.
Plates were fixed with 10% phosphate-buffered formalin (ThermoFisher Scientific), taken out of the BSL-4 facility and plaques were
counted using a fluorescence microscope.
Selection of VSV/BDBV-GP escape mutants
Themutated chimeric vesicular stomatitis viruses covered with BDBVGP (VSV/BDBV-GP) able to resist neutralization bymAbs were
selected as described earlier (Flyak et al., 2015). Briefly, 200 PFU of VSV/BDBV-GP (Mire et al., 2013) (provided by Dr. C. Mire and
Dr. T. Geisbert, UTMB) were pre-neutralized before each passage by two-fold serial mAb dilutions starting from 200 mg/mL for 1 hour
at 37C passaged several times in Vero E6 cells in the presence of corresponding amount of mAb for 2 days. After each passage,
harvested virus aliquots were titrated, and virus-positive sample with highest mAb concentrations were used for subsequent pas-
sage. Finally, virus plaques were grown under mAb-containing 0.7% agarose overlay for 5 days, visualized by neutral red staining,
purified, and used for propagation of VSV/BDBV-GP escape mutants in presence of corresponding mAb. GP of propagated viruses
were RT-PCR-amplified and sequenced, and mutants were assessed for their mAb resistance in a standard plaque reduction assay
compared to the initial VSV/BDBV-GP virus as described above for EBOV/BDBV-GP.
Confocal microscopy
THP-1 cells were grown in suspension, inoculated with EBOV/BDBV-GP at an MOI of 5 PFU/cell and fixed with 4% formaldehyde at
room temperature for 15 min. Cells were rehydrated with PBS, permeabilized with 0.5% Triton X-100 in PBS for 15 min and washed
three times with PBS to remove the permeabilization solution. Next, antigen was blocked with 5% donkey serum, 1% bovine serum
albumin and 0.1% Triton X-100 (PBS-BSA-TX100) in PBS for 1 hour. For EBOV/BDBV-GP staining, rabbit immune serum against
EBOV virus-like particles and anti-BDBV GP rabbit polyclonal antibodies (Integrated BioTherapeutics) were diluted at 1:100 each
in PBS-BSA-TX100. For co-staining of FcRs, murine mAbs specific for FcgRIII (clone GRM1, Southern Biotech) were added to
the anti-BDBV mixture at a 1:50 dilution, and then cells were incubated for one hour at room temperature and washed 5 times in
PBSwith 0.1%Triton X-100. Next, donkey anti-rabbit antibodies conjugated with AlexaFluor 647 (Invitrogen) and donkey anti-mouse
antibodies conjugated with AlexaFluor 488 (Invitrogen) were added at a 1:200 dilution, and cells were incubated for 1 hour at room
temperature. For humanmAb staining, donkey anti-human IgG conjugated with CF594 (catalog #SAB4600097, Sigma-Aldridge) was
added at 1:50 dilution and cells were incubated for 1 hour at room temperature. Slides were washed four times in PBS-BSA-TX100,Cell Reports 24, 1802–1815.e1–e5, August 14, 2018 e4
cells were fixed in 4% formaldehyde for 72 hours and removed from the BSL-4 facility. Next, cells were washed once with 0.5 M
glycine diluted in PBS, incubated with 6-diamin-2-phenylindole-dihydrochloride (DAPI) (Invitrogen) at 1 mg/mL for 2 min for nuclei
staining, andwashed five timeswith PBS. The slideswere washed andmounted onto coverslips using PermaFluor mountingmedium
(ThermoFisher Scientific) and visualized under confocal microscope. Laser scanning confocal microscopy was performed using an
Olympus FV1000 confocal microscope housed at the Galveston National Laboratory. All images were acquired using a 60x oil
objective.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses and generations of graphs were performed using GraphPad Prism version 6.05 (GraphPad Software). Statistical
significances were calculated using t test, multiple or unpaired. In the experiments with primary human immune cells (Figure 4),
statistical significancewas determined using the Holm-Sidakmethod, with a = 5%. For analysis of survival data in in vivo experiments
(Figure 5), log-rank (Mantel-Cox) test was used.e5 Cell Reports 24, 1802–1815.e1–e5, August 14, 2018
